Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT07176650. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Parallel-Controlled, Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Study identification
- NCT ID
- NCT07176650
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Enrollment
- 246 participants
Conditions and interventions
Conditions
Interventions
- HLX13 Drug
- OPDIVO Drug
- Yervoy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 24, 2025
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Mar 15, 2026
2025 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Oncology Physicians Network (OPN) - Los Alamitos /OPN Healthcare | Glendale | California | 91203 | Recruiting |
| Los Angeles Cancer Network | Glendale | California | 91204 | Not yet recruiting |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | Not yet recruiting |
| D&H National Research Centers, LLC | Margate | Florida | 33063 | Recruiting |
| Mid Florida Hematology and oncology Center | Orange City | Florida | 32763 | Recruiting |
| Florida Clinical Trials Group | Plantation | Florida | 33322 | Not yet recruiting |
| Florida Clinical Trials Group | Tamarac | Florida | 33321 | Not yet recruiting |
| HCA Research Institute, LLC | Brentwood | Tennessee | 37027 | Not yet recruiting |
| Oncology Consultants | Houston | Texas | 77030 | Recruiting |
| American Oncology Network Vista Oncology Division/Physician Partner Associate | Olympia | Washington | 98506 | Recruiting |
| Northwest Medical Specialties PLLC (NWMS) | Tacoma | Washington | 98405 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07176650, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07176650 live on ClinicalTrials.gov.